Several other analysts have also commented on the stock. Zacks Investment Research upgraded shares of ProQR Therapeutics from a “hold” rating to a “strong-buy” rating and set a $20.00 price target on the stock in a research report on Wednesday, January 9th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of ProQR Therapeutics in a research report on Thursday, February 28th. Chardan Capital reiterated a “buy” rating and issued a $25.00 target price (up previously from $21.00) on shares of ProQR Therapeutics in a research report on Tuesday, March 12th. Royal Bank of Canada began coverage on shares of ProQR Therapeutics in a research report on Wednesday, December 19th. They issued an “outperform” rating on the stock. Finally, Cantor Fitzgerald set a $40.00 target price on shares of ProQR Therapeutics and gave the company a “buy” rating in a research report on Tuesday, January 29th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $28.67.
Shares of ProQR Therapeutics stock traded up $0.26 during trading on Monday, hitting $11.47. 141,373 shares of the company’s stock were exchanged, compared to its average volume of 202,191. The company has a debt-to-equity ratio of 0.10, a current ratio of 13.28 and a quick ratio of 13.28. ProQR Therapeutics has a 52-week low of $3.45 and a 52-week high of $24.00. The stock has a market cap of $445.84 million, a PE ratio of -8.89 and a beta of 0.63.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
See Also: Book Value Per Share – BVPS
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.